Orforglipron Pre-Treatment Checklist: What to Tell Your Doctor

Before starting orforglipron (Foundayo), the FDA label points to a specific set of history, conditions, and medications worth raising with your prescriber first — thyroid and pancreas history, gallbladder disease, pregnancy status, and anything else you’re currently taking. This isn’t a substitute for that conversation; it’s a checklist so you walk into it prepared rather than caught off guard by a question you hadn’t thought about.

Why does orforglipron need a pre-treatment conversation?

Orforglipron is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, taken alongside diet and physical activity. Per its DailyMed label, it carries a boxed warning and several precautions that aren’t relevant to every patient — but they’re exactly the kind of thing that’s easy to forget to mention unless you’re specifically asked, or unless you know to bring it up yourself. The list below follows the label’s own structure: contraindications first, then precautions, then medications.

What medical history should you disclose before starting orforglipron?

Condition or history	Why it matters per the FDA label	Where to read more
Personal or family history of medullary thyroid carcinoma (MTC), or MEN 2	Contraindicated — orforglipron should not be used	Does Orforglipron Cause Thyroid Cancer?
History of pancreatitis	Label warns of acute pancreatitis risk; relevant to disclose before starting	Orforglipron and Pancreatitis
Gallbladder disease (gallstones, prior cholecystitis)	Label warns of cholelithiasis/cholecystitis risk	Orforglipron and Gallbladder Problems
Severe GI disease, including gastroparesis	May affect tolerability given how GLP-1s slow gastric emptying	Orforglipron and Gastroparesis
Diabetic retinopathy	Label flags monitoring considerations for patients with this history	Orforglipron and Vision Changes
Pregnant, trying to conceive, or breastfeeding	Label advises against use in pregnancy	Orforglipron and Pregnancy

This table isn’t exhaustive of everything in the label, and it isn’t a diagnostic tool — it’s a starting point for what to say out loud at your appointment, even if you think it isn’t relevant.

Is orforglipron contraindicated for you?

Per the FDA label, the one hard contraindication is a personal or family history of MTC or MEN 2 — if that applies to you, orforglipron isn’t an option, full stop. Everything else on the list above is a precaution, not an automatic disqualifier: having gallbladder disease or a pancreatitis history doesn’t necessarily rule orforglipron out, but it does change how closely your prescriber monitors you and what symptoms they’ll ask you to watch for. For a broader rundown of who the drug is and isn’t FDA-approved for, see Who Should Take Orforglipron?

What medications and supplements should you list before starting orforglipron?

Bring a complete list of everything you take — prescription, over-the-counter, and supplements — not just what feels relevant. The FDA label specifically calls out a few interaction points worth flagging in advance:

• Other GLP-1 receptor agonists. The label states concomitant use with another GLP-1 medication is not recommended, so if you’re currently on one, your prescriber needs to plan the transition. See Switching to Orforglipron for what that generally involves.
• Insulin or sulfonylureas. Combined use with these diabetes medications raises hypoglycemia risk, per drug-interaction guidance for the GLP-1 class.
• Other oral medications generally. Because GLP-1 receptor agonists can slow gastric emptying, your prescriber may want to review timing for other oral drugs. Our Orforglipron Drug Interactions guide covers the specifics the label addresses, including metformin, levothyroxine, statins, and NSAIDs.

Do you need lab tests before starting orforglipron?

A common question is whether you need bloodwork before your first dose. The honest answer, grounded in the label: there’s no mandated pre-treatment panel for people without risk factors. The label even states that routine calcitonin testing or thyroid ultrasound is of uncertain value for detecting the thyroid C-cell tumor risk in its boxed warning — meaning more testing isn’t automatically more informative. What actually drives any labs ordered before you start — a pregnancy test, baseline kidney function, or anything else — is your individual history as your prescriber assesses it, not a universal checklist this article can hand you.

What symptoms should you watch for before you start?

Part of being prepared is knowing what to watch for so you recognize it early instead of brushing it off as routine GI upset during the first few weeks. Per the FDA label, the symptoms tied to its key warnings are:

• Thyroid: a lump or swelling in the neck, persistent hoarseness, trouble swallowing, or trouble breathing.
• Pancreatitis: severe abdominal pain that may radiate to the back, sometimes with nausea and vomiting.
• Gallbladder: pain in the upper right abdomen, fever, or yellowing of the skin or eyes.
• Dehydration/kidney function: persistent vomiting or diarrhea, or noticeably reduced urination.

None of these are common, everyday reactions — they’re the specific red flags the label asks patients to report promptly. For what is common and expected, especially in the first weeks, Orforglipron Side Effects covers the typical GI adjustment period separately from these warning signs.

Bottom line

Walking into your first orforglipron conversation prepared means being ready to disclose thyroid and pancreatitis history, gallbladder disease, pregnancy status, and a complete medication list — and knowing which warning symptoms are worth reporting immediately rather than waiting out. None of this replaces your prescriber’s own assessment; it just means the conversation starts with the information that actually changes the plan, instead of getting discovered after the fact.